| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3947519 | Gynecologic Oncology | 2008 | 4 Pages |
Abstract
This is the first study to demonstrate that clinical trials applying murine monoclonal antibodies may be flawed by a transient HAMA effect, which should be considered when monitoring ovarian cancer patients with CA 125 measurements.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Angèle L.M. Oei, Fred C.G.J. Sweep, Leon F.A.G. Massuger, André J. Olthaar, Chris M.G. Thomas,